Evaluating the efficacy of compound MP-010 in lifespan in SOD1G93A mice
After observing that MP-010 treatment confers motor and electrophysiological benefits, leading to reduced MN loss, a second trial in SOD1G93A mice was conducted to investigate its potential to extend survival, particularly at the dosage of 61 mg/kg (Fig. 4A). Our observations revealed that MP-010-treated animals exhibited reduced weight loss compared to vehicle-treated controls, with significant differences becoming apparent at 18-19 weeks of age (Fig. 4B). The results obtained in the survival study indicated that MP-010 delayed mortality by approximately 7 days, extending the average lifespan from 132 ± 8.35 days in vehicle-treated SOD1G93A mice to 139 ± 10.92 days in MP-010-treated mice (Fig. 4C).
Analyzing the outcomes of the behavioral tests, we again observed that MP-010-treated SOD1G93A mice at the dose of 61 mg/kg demonstrated enhanced rotarod performance at advanced stages compared to vehicle-treated counterparts (Fig. 4D). Motor strength, assessed in the hanging-wire test, revealed no significant differences between the two groups of animals (Fig. 4E).